Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System

NCT ID: NCT05540223

Last Updated: 2025-11-21

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 1859 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-13
• Study Completion Date: 2032-02-29

Brief Summary

The objective of this study is to assess the safety and efficacy of the Freesolve in the treatment of subjects with up to two de novo lesions in native coronary arteries compared to a contemporary drug eluting stent (DES).

Detailed Description

The Biotronik BIOMAG-II clinical trial is a prospective, international, multi-center, randomized controlled, non-inferiority trial to compare the BIOTRONIK Sirolimus Eluting Resorbable Magnesium Scaffold System (Freesolve RMS) with the Xience Everolimus Eluting Stent System (Xience DES) with respect to Target Lesion Failure (TLF) rate at 12 months. A total of 1859 subjects will be enrolled at approximately 100 study sites Europe and APAC. Subjects will be randomized in a 2:1 ratio to Freesolve or Xience.

Clinical follow-up visits will take place at 1, 6, 12 and at 2-, 3-, 4- and 5-years post procedure.

Conditions

Coronary Artery Disease; Atherosclerosis, Coronary; Myocardial Ischemia; Ischemic Heart Disease; Acute Coronary Syndrome; Angina Pectoris

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Freesolve RMS

Intervention with a Freesolve Sirolimus Eluting Resorbable Coronary Magnesium Scaffold System

Group Type: EXPERIMENTAL

Freesolve RMS

Intervention Type: DEVICE

Subject undergoes implantation of Freesolve RMS

Xience DES

Intervention with a Xience Everolimus Eluting Stent System

Group Type: ACTIVE_COMPARATOR

Xience DES

Intervention Type: DEVICE

Subject undergoes implantation of Xience DES

Interventions

Freesolve RMS

Subject undergoes implantation of Freesolve RMS

Intervention Type: DEVICE

Xience DES

Subject undergoes implantation of Xience DES

Intervention Type: DEVICE

Other Intervention Names

DREAMS 3G Sirolimus Eluting Resorbable Coronary Magnesium Scaffold System; Xience Everolimus Eluting Stent System

Eligibility Criteria

Inclusion Criteria

1. Subject is ≥ 18 years and ≤ 80 years of age

2. Subject has provided written informed consent as approved by the Independent Ethical Committee (IEC) or Institutional Review Board (IRB) of the respective clinical site prior to the study related procedures

3. Subject is eligible for PCI according to the applicable guidelines

4. Subject is an acceptable candidate for coronary artery bypass surgery

5. Subjects with stable or unstable angina pectoris, documented silent ischemia/abnormal physiologic testing or hemodynamically stable non-ST elevation myocardial infarction (NSTEMI) patients without angiographic evidence of thrombus at target lesion

Note: STEMI patients may be eligible for the study for treatment of selected non-culprit lesions, if:

1. Subjects with a maximum of two single de novo target lesions each in separate native coronary arteries

2. Target vessel must have a reference diameter between 2.5-4.2 mm by visual estimation, which may be assisted by Quantitative Coronary Angiography (QCA) / Intravascular Ultrasound (IVUS) / Optical Coherence Tomography (OCT)

3. Target lesion must be ≤28mm in length by operator visual estimation, which may be assissted by QCA / IVUS / OCT, (or < 20 mm for target lesion(s) to be treated with a study device < 3.0 mm in diameter) and should be amenable to treatment with a single study device

4. Target lesion stenosis ≥ 50% and < 100% by operator visual estimation, which may be assisted by QCA / IVUS / OCT. Target lesion stenosis < 70% by visual estimation, should have clinical justification for treatment as per local standards.

5. Target lesion must have a Thrombolysis In Myocardial Infarction (TIMI) flow ≥1

Exclusion Criteria

• Subject is hemodynamically stable with documented declining cardiac biomarkers;
• Target lesion(s) to be treated are not located in the culprit vessel(s) and are not culprit lesion(s)

6. Subject is eligible for Dual Antiplatelet Therapy (DAPT) with aspirin plus either clopidogrel, prasugrel, ticagrelor or ticlopidine

7. Documented left ventricular ejection fraction (LVEF) ≥ 30% within 6 months prior to or during the procedure (prior to randomization)

8. Subject is willing and able to comply with protocol requirements, including completion of study visits for the duration of the study

1. Subject is pregnant and/or breastfeeding or intends to become pregnant during the duration of the study

2. Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with STEMI < 72 hours prior to the index procedure.

Note: Hemodynamically stable non-STEMI (NSTEMI) subjects are eligible for study enrollment.

3. Subject has undergone prior PCI within the target vessel during the last 12 months prior to the index procedure or prior PCI within a non-target vessel <72 hours prior to the index procedure if successful and uncomplicated

4. Subject is on dialysis or with impaired renal function (serum creatinine > 2.5 mg/dL or 221 µmol/L, determined within 72 hours prior to the index procedure)

5. Subject has a known allergy to contrast medium that cannot be adequately premedicated, or any known allergy to aspirin, P2Y12 inhibitors, both heparin and bivalirudin, sirolimus, everolimus (or similar limus drugs), poly L-lactide, the scaffold material (magnesium, aluminium, tantalum), or Xience stent material (cobalt, chromium, tungsten, nickel, -methacrylic polymer, and fluoropolymer)

6. Subject is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are permitted) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus; diabetes mellitus is permitted)

7. Life expectancy less than 1 year

8. Planned surgery or dental surgical procedure within 6 months after index procedure, unless DAPT can be maintained

9. In the investigator's opinion subject will not be able to comply with the follow-up requirements

10. Subjects under oral anticoagulation therapy (OAC) prior to index procedure unless DAPT + OAC (i.e. triple therapy) can be maintained for a minimum of 1 month

11. Subject has had a stroke or transient ischemic attack (TIA) within 6 months prior to the index procedure

12. Subject with active bleeding disorder, active coagulopathy, or any other reason, who is ineligible for DAPT

13. Subject is currently participating or plans to participate in another study with an investigational device or an investigational drug

1. Target vessel has been previously treated and the target lesion is within 5 mm proximal or distal to the previously treated lesion

2. Left main coronary artery disease

3. Target lesion was totally occluded (100% stenosis)

4. Thrombus in target vessel

5. Future planned staged PCI either in target or non-target vessel

6. Ostial target lesion within the left descending (LAD), left circumflex (LCx), or right coronary artery (within 5.0 mm of vessel origin)

7. Target lesion involves a side branch ≥ 2.0 mm in diameter that requires a two-device strategy after pre-dilatation

8. Target lesion is located in or supplied by an arterial or venous bypass graft

10. The target lesion requires treatment with the device other than the non-compliant balloon and/or cutting/scoring balloon prior to scaffold/stent placement (including but not limited to atherectomy devices, intravascular lithotripsy, drug-coated balloons etc.)

11. Target vessel was treated with brachytherapy any time prior to the index procedure.

12. Unsuccessful pre-dilatation, defined as residual stenosis > 20% (by visual estimation) and / or angiographic complications (e.g. distal embolization, side branch closure, flow-limiting dissections)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Biotronik AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Haude, MD

Role: PRINCIPAL_INVESTIGATOR

Rheinland Klinikum Neuss GmbH Lukaskrankenhaus Neuss

Locations

Rheinland Klinikum Neuss GmbH Lukaskrankenhaus Neuss

Neuss, , Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

Barbara Widmann, PhD

Role: CONTACT

barbara.widmann@teleflex.com

0041 75 429 5530

Nadine Kluser

Role: CONTACT

nadine.kluser@teleflex.com

0041 75 429 54 82

Facility Contacts

Michael Haude, Prof. Dr.

Role: primary

michael.haude@rheinlandklinikum.de

+49 2131 888 2000

Other Identifiers

BIOMAG-II - EU, Asia and AUS

Identifier Type: OTHER

Identifier Source: secondary_id

C1801

Identifier Type: -

Identifier Source: org_study_id